|1.50|| +0.04 / +2.74%|
Echo Therapeutics is a medical device company with deep expertise in advanced skin permeation technology. It develops non-invasive, wireless continuous glucose monitoring (CGM) system with potential use in the wearable-health consumer market and the diabetes outpatient market. The company is developing its Prelude SkinPrep System as a platform technology to allow for enhanced skin permeation that will enable two important applications: Analyte extraction, with the Symphony CGM System for needle-free, continuous glucose monitoring in critical patients as the first application and Needle-free drug delivery, with the delivery of lidocaine as the first application. Echo Therapeutics was founded on September 14, 2007 and is headquartered in Iselin, NJ.
|Scott Wayne Hollander||President, Chief Executive Officer & Director|
|Thomas H. Bishop||Vice President-Operations & Product Development|
|Alan Wayne Schoenbart||Chief Financial Officer & Secretary|
|Christine H. Olimpio||Director-Investor Relations & Communications|